The plasma protein treatment cycle is complicated and closely monitored to ensure process efficacy and safety donor safety, biological licensing, compliance, and pharmacovigilance. The global need for immunoglobulin is rising due to an increase in the prevalence of primary immunodeficiencies (PID). As a result, the number of clinical applications has risen, including autoimmune and acute inflammatory illnesses.
The market for plasma protein therapeutics will grow at a strong CAGR of 7.1%, from a value of $27.20 billion in 2021 to $50.4 billion by 2030.
The global market for plasma protein therapies is very competitive and subject to strict restrictions. In developed regions, plasma collection standards are excellent, and a tight regulatory structure is in place to preserve operational quality. Health authorities monitor the fractionation process to prevent poor plasma quality and guarantee that the source plasma is free of infectious agents like Parvovirus B, hepatitis A, B, and C, and HIV.
Market Dynamics
Drivers
Due to the plasma protein's useful features, the market is now experiencing an increased demand for sophisticated therapeutic treatments, fueling the industry's expansion. Additionally, the government supports the development of the healthcare sector and the favorable reimbursement practices of health insurance investment firms, fueling the market's expansion. The development of plasma protein therapies and the production of sophisticated delivery systems for these treatments, combined with ongoing technological improvements in the extraction and separation of plasma, are driving the worldwide plasma protein therapeutics market.
Restraints
The implementation of plasma therapy may be hampered by the imposition of rigid guidelines and rules for handling plasma protein products and by the absence of reimbursement plans. These main factors hinder the market for plasma protein therapies from expanding.
Opportunity
In the coming years, opportunities may arise as people become more aware of autoimmune diseases (such as Von Willebrand disease, antithrombin III deficiency, cardiopulmonary disease, chronic inflammatory demyelinating polyneuropathy, and hepatitis), organ transplants (such as liver surgery and pediatric HIV), and cases of burns that result in trauma among people.
Market Segmentation
Product Insights
The plasma protein therapies market is divided into albumin, immunoglobulins (IG), plasma-derived factor VIII, and others based on the kind of product. Immunoglobulin took the top spot in 2021 with a market share of more than 45.42%. The widespread acceptance of biologics for various purposes, simplicity of administration, and high cost of care are all to blame for the high percentage.
The enhanced detection of hypoalbuminemia brought on by liver cirrhosis and hepatitis B is predicted to contribute to the albumin segment's large market growth during the projection period. As albumin's largest market, China's high demand and consumption are expected to enhance the expansion.
Application Insights
In 2020, the Haemophilia sector held the greatest market share of around 45%. More than 1,125,000 men worldwide suffer from an inherited bleeding illness, and 418,000 of them have a severe form of the most underdiagnosed disease, according to the Global Hemophilia Care report. Factors like the rising number of life-threatening diseases, the growing geriatric population, changes in dietary habits, and the adoption of a sedentary lifestyle are driving the segment's overall expansion.
Regional Insights
North America and Europe account for around 70.26% of the market. The U.S. led the North American market with a share of more than 40.47% in 2021. Some of the important geographical drivers include the presence of a sizable patient base, an increasing geriatric population, and the availability of a well-developed infrastructure for storing and keeping high-quality source plasma. Some other major regional expansion drivers include rising disease prevalence and increased use of innovative therapies.
Key Players
The market for plasma protein therapies will grow at a strong CAGR of 7.1%, from a value of $27.20 billion in 2021 to $50.4 billion by 2030. The primary driver of the growth of the global plasma protein therapeutics market is the rising demand for plasma protein therapeutics for the treatment of autoimmune neurologic diseases, acute cardiomyopathy, multifocal motor neuropathy (MMN), hemolytic disease of the newborn, autoimmune mucocutaneous blistering diseases, and acute panautonomic polyneuropathy.
Transparency Market Research (TMR) has published a new report titled, ‘Plasma Protein Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027’.
According to the report, the Plasma Protein Therapeutics Market was valued at US$ 22,413.9 Mn in 2018 and is projected to expand at a CAGR of 7.0% from 2019 to 2027.Request Brochure – https://www.transparencymarketresearch.com/sample/sample.php?flag=B_id=10424OverviewPlasma-derived therapies and their recombinant analogs, collectively referred to as plasma protein therapies, are unique, biologic medicines, versus synthetic or chemical medicines, because production begins with plasma, a biologic starting material.Stringent Regulations and Reimbursement Issues, diagnosis rate, public awareness and high price of the biological are the major market barrier.
High demand in plasma protein therapeutic proteins and medicinal use in new indications, penetration of existing indications, better access to medicines in emerging markets, aging population, and new plasma-derived therapies are likely to drive the market.North America is poised to cover a high share in2018, while Asia Pacific is poised to grow at a highest CAGR in the forecast.
There is a growing demand of Albumin in Asia Pacific market, followed by Latin America.Request COVID Analysis on Plasma Protein Therapeutics Market – https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19_id=10424Growing Investment in Innovation, Rising Demand for Immunoglobulin (IG) and Rising Indications and Therapeutic use of Plasma Derived Protein Therapeutics to Drive MarketThe plasma protein industry has been investing in research and development of new plasma proteins therapies (e.g.
In March 2016, Grifols announced that it will invest US$ 360 Mnto expand its production capabilities for plasma-derived therapies.
The therapies include: Immunoglobulin's used to treat a number of diseases in individuals with immune deficiencies and autoimmune diseases, Clotting-factor therapies used for individuals with hemophilia A and B and other bleeding disorders, Albumin, which is used in acute settings to treat individuals with shock, trauma, burns and other conditions.
The newly added Plasma Protein Therapeutic market research report by Value Market Research disclose all the important information associated with the market such as value, growth factor, trends, market share, size, and challenges for the forecasted timeline 2020-2027.
Basically, this report is designed to give a proper understanding of industry structure and competition intensity attractiveness.The report also covers detailed competitive landscape including company profiles of key players operating in the global market.
The key players in the plasma protein therapeutic market include Baxter, Biotest, Chengdu Inst., China Biologics, CSL Behring, Grifols, Kedrion, Octapharma, and Shire Plc.
An in-depth view of the competitive outlook includes future capacities, key mergers & acquisitions, financial overview, partnerships, collaborations, new product launches, new product developments and other developments with information in terms of H.Q.Get more information on "Global Plasma Protein Therapeutic Market Research Report" by requesting FREE Sample Copy at https://www.valuemarketresearch.com/contact/plasma-protein-therapeutic-market/download-sampleMarket DynamicsThe increasing applications of plasma proteins in the pharmaceutical industry are driving market growth.
Additionally, growing expenditure in the healthcare industry along with the introduction of new plasma-based therapies is further fuelling market growth.
On the other hand, slower approval procedure and implementation of stringent regulation policies may restrict market growth.
The global Plasma-Derived Protein Therapies Market research report, published by Value Market Research, is designed to offer various market framework such as market size, portion, trends, growth path, value and factors that impact the current market dynamics over the forecast period 2020-2027.
Most importantly, this report also provides the latest significant strategies adopted by major players along with their market share.The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide.
The major players in the plasma-derived protein therapies market include CSL Behring LLC, Octapharma AG, Biotest AG, Kedrion S.P.A, Bayer AG and Grifols S.A.
This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.Get more information on "Global Plasma-Derived Protein Therapies Market Research Report" by requesting FREE Sample Copy at https://www.valuemarketresearch.com/contact/plasma-derived-protein-therapies-market/download-sampleMarket DynamicsThe usage of plasma derived protein in medical application has increased sustainably in recent years.
Growing focus and rising investment in innovation is expected to fuel the growth of the market over the forecast period.
Apart from this, rising expenditure on biotechnology and continuous research and development activities in plasma derived protein therapies is boosting the market during the forecast period.
